Proactive Investors - Run By Investors For Investors

PDS Biotechnology shares pop on positive medical journal article

The article explains how Versamune, the company’s cancer immunotherapy platform, activates T-cells to identify and attack cancer cells
Blood cells
The article explored how Versamune, the company’s cancer immunotherapy platform, activates T-cells to identify and attack cancer cells

Shares of PDS Biotechnology Corporation (NASDAQ:PDSB) exploded Wednesday on news that an article supporting its signature cancer treatment platform will be published in the Journal of Immunology’s June issue.

The article explains how Versamune, the company’s cancer immunotherapy platform, activates T-cells to identify and attack cancer cells, while making the cancer cells more vulnerable to attack.

The New Jersey company’s stock soared 43% to US$8.80.

The piece examines a preclinical study conducted at University of Kentucky School of Medicine, which corroborated the results of earlier preclinical studies regarding the immunological activity of PDS’ proprietary lipid molecule.

"As a cancer immunologist who has spent the last decade performing translational and clinical research in immuno-oncology at the National Cancer Institute, the versatility of PDS’ Versamune technology, and the strength of this recently published data, demonstrates Versamune’s potential to provide significant advancements in the treatment of various cancers and debilitating diseases,” said Chief Medical Officer Lauren Wood. 

Contact Andrew Kessel at [email protected]

Follow him on Twitter @andrew_kessel

View full PROAC profile View Profile

Proactiveinvestors Timeline

Related Articles

books
May 22 2019
Here we take a closer look at Bloomsbury Publishing PLC (LON:BMY)
Augmented Reality on phone
March 21 2019
The firm currently has around nine companies in its portfolio that are either direct investments or through its sub-fund, Suir Valley Ventures, in which it holds a 22% stake
Live Company
June 13 2019
In June 2019 the company signed a five-year deal to create tours themed around properties owned by children’s television network Nickelodeon

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use